Washington, D.C. 20549


Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934 (Amendment No.       )

Filed by the Registrant   [X]
Filed by a Party other than the Registrant   [_]

Check the appropriate box:

[_] Preliminary Proxy Statement
[_] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (as permitted by Rule 14a-6(e)(2))
[_] Definitive Proxy Statement
[X] Definitive Additional Materials
[_] Soliciting Material Pursuant to Section 240.14a-12

Pfizer Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

[X] No fee required.
[_] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
1) Title of each class of securities to which transaction applies:

2) Aggregate number of securities to which transaction applies:

3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

4) Proposed maximum aggregate value of transaction:
5) Total fee paid:
[_] Fee paid previously with preliminary materials:
[_]  Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.
  1) Amount previously paid:

  2) Form, Schedule or Registration Statement No.: 

  3) Filing Party: 

  4) Date Filed:



Pfizer Inc

235 East 42nd Street

New York, NY 10017




Dear Fellow Pfizer Shareholder:


On April 25, 2019, Pfizer will hold its Annual Meeting of Shareholders in Short Hills, New Jersey. We value your input as a holder of Pfizer common stock, and encourage you to review our proxy materials and cast your vote today. You can view our proxy materials at https://investors.pfizer.com/proxy.


For the reasons set forth in the 2019 Proxy Statement, the Board of Directors recommends that you vote:


· “FOR” each director nominee;
· “FOR” the ratification of the selection of KPMG LLP as the independent registered public accounting firm for 2019;
· “FOR” the 2019 advisory approval of executive compensation;
· “FOR” the approval of the Pfizer Inc. 2019 Stock Plan; and
· “AGAINST” the four shareholder proposals.


For your convenience, a duplicate proxy/voting instruction card and return envelope are enclosed, along with telephone and Internet voting instructions. In the event that multiple proxies/voting instruction cards are received from you, the one with the latest date will be counted.


Thank you for your investment in Pfizer. Please vote your shares today.



Margaret M. Madden

Senior Vice President and Corporate Secretary, Chief Governance Counsel